Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib in Metastatic or Recurrent Breast Cancer
NCT00045591Phase 2Terminated
- Sponsor
- Cancer and Leukemia Group B
- Start
- Feb 2003
- Primary completion
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of celecoxib oral solution in breast cancer (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Progression-Free Survival at 28 months. Started Feb 2003; status: terminated.
02
Drugs
celecoxib oral solution
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00045591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00045591.